Sinovac Life Sciences Co., Ltd.
Clinical trials sponsored by Sinovac Life Sciences Co., Ltd., explained in plain language.
A Chinese biopharmaceutical company focused on vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New 24-Valent vaccine aims to shield children from more pneumonia strains Results expected Sep 2026 (estimated)
- New meningitis vaccine enters first human tests Results expected Sep 2026 (estimated)
- New shot aims to block deadly tetanus after dirty wounds Results expected Mar 2027 (estimated) 🚀 Make-or-break
- New baby vaccine could fight pneumonia Results expected Jul 2027 (estimated) 🚀 Make-or-break
-
New baby vaccine could fight pneumonia
Vaccine Not yet recruitingThis study tests a new vaccine to protect babies against pneumococcal infections, which can cause pneumonia and meningitis. About 500 healthy infants will receive either the new vaccine or an existing one. Researchers will check if the new vaccine triggers a strong immune respons…
Phase 3 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 12:35 UTC
-
New meningitis vaccine enters first human tests
Vaccine Not yet recruitingThis early-stage trial is testing a new vaccine designed to protect against several types of meningococcal bacteria, which can cause meningitis and bloodstream infections. Researchers will enroll 150 healthy people aged 2 to 59 to check the vaccine's safety and how well it trigge…
Phase 1 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
-
New shot aims to block deadly tetanus after dirty wounds
Prevention Not yet recruitingThis study tests a new medicine called SNA02-48 to see if it can prevent tetanus in people who have had a high-risk wound, like a deep cut or puncture from a dirty object. About 600 adults will receive either the new injection or the standard treatment (human tetanus immunoglobul…
Phase 3 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC